To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Ryogen Licenses Human Aminopeptidase P Gene Patent to OriGene
Ryogen LLC and OriGene Technologies Inc. have announced that they have entered into a nonexclusive license agreement whereby OriGene has licensed from Ryogen the patent directed to the clinically important Aminopeptidase P gene.
The US Patent No. 6,399,349 titled "Human Aminopeptidase P Gene," which is the subject of the License Agreement, covers the XPNPEP2 gene that codes for the clinically important protein, membrane-bound aminopeptidase P (AmP) discovered by Dr. James Ryan in the sixties.
Dr. Ryan, the Chief Scientist of Ryogen, subsequently sequenced the XPNPEP2 gene that codes for the AmP.
This patent covers the cDNA and gDNA sequences encoding AmP, a method of producing recombinant AmP, diagnostics for detecting AmP abnormalities, and prevention and treatment of medical conditions, associated with the mutation of the AmP gene.
"We are happy to extend a license under the AmP Patent to OriGene Technologies," said Valeria Poltorak, Ryogen's Vice President.
"We look forward to working with OriGene to make this important discovery available for research applications," she concluded.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
